# Task C23: Continuation of Oxfendazole Stability Studies

> **NIH NIH N01** · SRI INTERNATIONAL · 2024 · $63,336

## Abstract

The Non-clinical Services for Development of Interventional Agents for Infectious Diseases program provides services to facilitate preclinical product development of promising therapeutics for infectious disease-causing pathogens and/or toxins. Services include: preclinical product development planning and evaluation; lead identification and development; chemistry and GMP manufacturing; in vitro and in vivo preclinical microbiological, safety, toxicology and pharmacokinetics.

## Key facts

- **NIH application ID:** 11080840
- **Project number:** 272201800001I-0-759302400001-1
- **Recipient organization:** SRI INTERNATIONAL
- **Principal Investigator:** JON MIRASILAS
- **Activity code:** N01 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2024
- **Award amount:** $63,336
- **Award type:** —
- **Project period:** 2023-12-15 → 2024-12-14

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/11080840

## Citation

> US National Institutes of Health, RePORTER application 11080840, Task C23: Continuation of Oxfendazole Stability Studies (272201800001I-0-759302400001-1). Retrieved via AI Analytics 2026-05-22 from https://api.ai-analytics.org/grant/nih/11080840. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*